{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:12:24Z","timestamp":1781727144149,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":3144,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jpain.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T11:26:28Z","timestamp":1416223588000},"page":"164-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example"],"prefix":"10.1016","volume":"16","author":[{"given":"David W.","family":"Dodick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Turkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"DeGryse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena K.","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa E.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.jpain.2014.11.004_bib1","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society","volume":"8","year":"1988","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"10.1016\/j.jpain.2014.11.004_bib2","first-page":"9","article-title":"The International Classification of Headache Disorders: 2nd edition","volume":"24","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib5","series-title":"The HIT-6\u2122: A User's Guide","author":"Bayliss","year":"2002"},{"key":"10.1016\/j.jpain.2014.11.004_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0333102410384886","article-title":"Levetiracetam in chronic daily headache: A double-blind, randomised placebo-controlled study (The Australian KEPPRA Headache Trial [AUS-KHT])","volume":"31","author":"Beran","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2014.11.004_bib8","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: A randomized controlled trial","volume":"291","author":"Brandes","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jpain.2014.11.004_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1526-4637.2001.01041.x","article-title":"Designing pain research from the patient's perspective: What trial end points are important to patients with chronic pain?","volume":"2","author":"Casarett","year":"2001","journal-title":"Pain Med"},{"key":"10.1016\/j.jpain.2014.11.004_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jclinepi.2005.05.010","article-title":"Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test","volume":"59","author":"Coeytaux","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpain.2014.11.004_bib13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1468-2982.2009.01852.x","article-title":"Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1","volume":"29","author":"Cole","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: A clinically\u00a0useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jpain.2014.11.004_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline in the prophylactic treatment of\u00a0migraine and chronic daily headache","volume":"51","author":"Couch","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for\u00a0treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1526-4610.2007.00950.x","article-title":"The impact of topiramate on health-related quality of life indicators in chronic migraine","volume":"47","author":"Dodick","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled results\u00a0from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib20","article-title":"FDA's Temple discusses how to measure drug efficacy when mean effect is limited","author":"Dombrowski","year":"2010","journal-title":"The Pink Sheet"},{"key":"10.1016\/j.jpain.2014.11.004_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1526-4610.2004.446005.x","article-title":"Impact of headache on quality of life in a general\u00a0population survey in France (GRIM2000 Study)","volume":"44","author":"Duru","year":"2004","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT\u00a0recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2014.11.004_bib23","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/S1098-3015(10)72688-7","article-title":"Validating use of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) across migraine disorders","volume":"13","author":"Elson","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jpain.2014.11.004_bib24","unstructured":"Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 24(Suppl 1):9-160, 2004"},{"key":"10.1016\/j.jpain.2014.11.004_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: The HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jpain.2014.11.004_bib26","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2014.11.004_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpain.2012.12.006","article-title":"Anxiety\u00a0and depression are associated with migraine and pain in general: An investigation of the interrelationships","volume":"14","author":"Ligthart","year":"2013","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2014.11.004_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: A\u00a0population-based case-control study","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2014.11.004_bib29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves\u00a0quality of life and reduces impact of chronic migraine","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2014.11.004_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","article-title":"Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1)","volume":"40","author":"Martin","year":"2000","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of onabotulinumtoxinA (BOTOX\u00ae) and topiramate (TOPAMAX\u00ae) for the prophylactic treatment of chronic migraine: A pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1526-4610.2001.041006573.x","article-title":"Quality-of-life differences between patients with episodic and transformed migraine","volume":"41","author":"Meletiche","year":"2001","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: A systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpain.2014.11.004_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd edition (beta version)","volume":"33","author":"Olesen","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1526-4610.1994.hed3406337.x","article-title":"Measuring the functional status and well-being of patients with migraine headache","volume":"34","author":"Osterhaus","year":"1994","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1526-4610.2012.02155.x","article-title":"Self-reported comorbid pains in severe headaches or migraines in a US national sample","volume":"52","author":"Plesh","year":"2012","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","article-title":"The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients","volume":"22","author":"Rendas-Baum","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jpain.2014.11.004_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12955-014-0117-0","article-title":"Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine","volume":"12","author":"Rendas-Baum","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jpain.2014.11.004_bib39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1526-4610.2002.02122.x","article-title":"Chronic daily headache prophylaxis with tizanidine: A double-blind, placebo-controlled, multicenter outcome study","volume":"42","author":"Saper","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1526-4610.1994.hed3409497.x","article-title":"Double-blind trial of fluoxetine: Chronic daily headache and migraine","volume":"34","author":"Saper","year":"1994","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","article-title":"Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures","volume":"49","author":"Silberstein","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","article-title":"Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults","volume":"28","author":"Silberstein","year":"2008","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.47.4.871","article-title":"Classification of daily and near-daily headaches: Field trial of revised IHS criteria","volume":"47","author":"Silberstein","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2014.11.004_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1526-4610.2009.01481.x","article-title":"Headache prophylaxis\u00a0with BoNTA: Patient characteristics","volume":"50","author":"Silberstein","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jpain.2014.11.004_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in migraine prevention: Results of a large controlled trial","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jpain.2014.11.004_bib47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1468-2982.2003.00592.x","article-title":"Topiramate in the treatment of chronic migraine","volume":"23","author":"Silvestrini","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib48","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/01.WNL.0000100121.58594.11","article-title":"Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controlled study","volume":"61","author":"Spira","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jpain.2014.11.004_bib49","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1468-2982.2000.00117.x","article-title":"Guidelines for\u00a0controlled trials of drugs in migraine: Second edition","volume":"20","author":"Tfelt-Hansen","year":"2000","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2014.11.004_bib50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.pain.2012.12.010","article-title":"Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: Results of the German Headache Consortium study","volume":"154","author":"Yoon","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2014.11.004_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10194-008-0002-5","article-title":"The effect of sodium valproate on chronic daily headache and its subgroups","volume":"9","author":"Yurekli","year":"2008","journal-title":"J Headache Pain"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590014010232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590014010232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:58:08Z","timestamp":1761508688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590014010232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1526590014010232"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2014.11.004","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}